Javascript must be enabled to continue!
Haemodialysis with low dialysate flow rates: A comparison of high performance membranes and conventional membranes
View through CrossRef
Summary: We performed experimental studies to examine the effects of low dialysate flow rates on the clearance of small molecular weight substances, a middle molecular weight substance and a low molecular weight protein using a high performance membrane (HPM) and a conventional membrane (CVM). the blood flow rate was 200 mL/min and the diasylate flow rate varied between 300 and 500 mL/min. Clearance of urea and creatinine, representing small molecular weight substances, clearance of vitamin B12 representing a middle molecular weight substance, and clearance of myoglobin, representing a middle molecular weight substance, and clearance of myoglobin, representing a low molecular weight protein were measured. Lowering the dialysate flow rate from 500 to 300 mL/min in the HPM decreased the clearance of urea, creatinine, vitamin B12 and myoglobin by 7.2%, 8.6%, 8.4%, and 2.4%, respectively. Lowering the dialysate flow rate from 500 to 300 mL/min in the CVM decreased the clearance of urea, creatinine, and vitamin B12 by 8.7%, 10.9%, and 10.4%, respectively. Changes in the clearance of creatinine with reduced dialysate flow rate in the HPM were significantly lower than those in the CVM (P<0.05). Clearance of urea, creatinine, and vitamin B12 in the HPM at a dialysate flow rate of 300 mL/min were higher than those of in the CVM at a dialysate flow rate of 500 mL/min. These results suggest that dialysate flow rates can be reduced and water can be effectively saved by combining a dialysate flow rate of 300 mL/min with a HPM during water shortages due to natural disasters or climate changes.
Title: Haemodialysis with low dialysate flow rates: A comparison of high performance membranes and conventional membranes
Description:
Summary: We performed experimental studies to examine the effects of low dialysate flow rates on the clearance of small molecular weight substances, a middle molecular weight substance and a low molecular weight protein using a high performance membrane (HPM) and a conventional membrane (CVM).
the blood flow rate was 200 mL/min and the diasylate flow rate varied between 300 and 500 mL/min.
Clearance of urea and creatinine, representing small molecular weight substances, clearance of vitamin B12 representing a middle molecular weight substance, and clearance of myoglobin, representing a middle molecular weight substance, and clearance of myoglobin, representing a low molecular weight protein were measured.
Lowering the dialysate flow rate from 500 to 300 mL/min in the HPM decreased the clearance of urea, creatinine, vitamin B12 and myoglobin by 7.
2%, 8.
6%, 8.
4%, and 2.
4%, respectively.
Lowering the dialysate flow rate from 500 to 300 mL/min in the CVM decreased the clearance of urea, creatinine, and vitamin B12 by 8.
7%, 10.
9%, and 10.
4%, respectively.
Changes in the clearance of creatinine with reduced dialysate flow rate in the HPM were significantly lower than those in the CVM (P<0.
05).
Clearance of urea, creatinine, and vitamin B12 in the HPM at a dialysate flow rate of 300 mL/min were higher than those of in the CVM at a dialysate flow rate of 500 mL/min.
These results suggest that dialysate flow rates can be reduced and water can be effectively saved by combining a dialysate flow rate of 300 mL/min with a HPM during water shortages due to natural disasters or climate changes.
Related Results
A STUDY ON DIALYSATE GLUCOSE CONCENTRATION IN PATIENTS WITH CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
A STUDY ON DIALYSATE GLUCOSE CONCENTRATION IN PATIENTS WITH CONTINUOUS AMBULATORY PERITONEAL DIALYSIS
Background: Glucose-based peritoneal dialysis (PD) is the predominantly used dialysate in PD patients. Glucose absorption in peritoneal dialysis (PD) patients may contribute to adv...
pO2 and pCO2 Increment in Post‐dialyzer Blood: The Role of Dialysate
pO2 and pCO2 Increment in Post‐dialyzer Blood: The Role of Dialysate
Abstract: Blood returning from a dialyzer during hemodialysis has a higher pO2 and pCO2 content than blood entering the dialyzer, and this has been attributed to the dialysate. Th...
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort
ABSTRACTBackgroundLymphocyte ratios reflect inflammation and have been associated with adverse outcomes in a range of diseases. We sought to determine any association between neutr...
Development of a New Method for Pulse Push/Pull Hemodialysis
Development of a New Method for Pulse Push/Pull Hemodialysis
Although hemodiafiltration is presumed to be a gold standard for higher convective therapy for kidney failure patients, the repetition of forward and backward filtration during hem...
Microdialysis probe for transcutaneous monitoring of ethanol and glucose in humans
Microdialysis probe for transcutaneous monitoring of ethanol and glucose in humans
A heated (42 degrees C) microdialysis probe and its application for continuous transcutaneous sampling of ethanol and glucose through cellophane-stripped forearm skin are described...
Multiphase Flow Metering:An Evaluation of Discharge Coefficients
Multiphase Flow Metering:An Evaluation of Discharge Coefficients
Abstract
The orifice discharge coefficient (CD) is the constant required to correct theoretical flow rate to actual flow rate. It is known that single phase orifi...
MO722: Cardiac Biomarkers (NT-proBNP, Troponin I) and Heart Failure in Haemodialysis Patients
MO722: Cardiac Biomarkers (NT-proBNP, Troponin I) and Heart Failure in Haemodialysis Patients
Abstract
BACKGROUND AND AIMS
Patients with chronic kidney disease (CKD) stage 5 on haemodialysis are at a high risk of cardiovas...
THE ANTICOAGULANT THERAPY OF HAEMODIALYSIS PATIENTS WITH ACUTE CORONARY SYNDROME
THE ANTICOAGULANT THERAPY OF HAEMODIALYSIS PATIENTS WITH ACUTE CORONARY SYNDROME
Objectives
To evaluate the effect of different dose of anticoagulants in haemodialysis patients with acute coronary syndrome (not including ST-elevate myocardial ...

